STOCK TITAN

Tarsus: Paradigm BioCapital Advisors reports 4.7% stake

Available on EDGAR Accepted by SEC EDGAR Learn about SEC filing dates
(Neutral)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Form Type
SCHEDULE 13G/A

Rhea-AI Filing Summary

Tarsus Pharmaceuticals, Inc. (TARS) is the issuer whose common stock is covered by this amended ownership report. As of September 30, 2026, Paradigm BioCapital Advisors LP, Paradigm BioCapital Advisors GP LLC and Senai Asefaw, M.D. each reported beneficial ownership of 2,301,375 shares, or 4.7% of the class. Paradigm BioCapital International Fund Ltd. reported 2,028,487 shares, or 4.1%. The Adviser, its general partner and Asefaw may be deemed to beneficially own shares held directly by the Fund and managed accounts, so their reported positions overlap rather than represent additional shares. The reported percentages use 49,303,413 shares outstanding as of September 25, 2026.

Beneficial ownership reported by Adviser, Adviser GP and Senai Asefaw 2,301,375 shares Each reported this amount as of September 30, 2026.
Ownership percentage reported by Adviser, Adviser GP and Senai Asefaw 4.7% Each reported this percentage as of September 30, 2026.
Fund beneficial ownership 2,028,487 shares Reported by Paradigm BioCapital International Fund Ltd. as of September 30, 2026.
Fund ownership percentage 4.1% Reported by Paradigm BioCapital International Fund Ltd. as of September 30, 2026.
Shares outstanding 49,303,413 shares Tarsus common stock outstanding as of September 25, 2026; basis for reported ownership percentages.
beneficial ownership regulatory
"Amount beneficially owned: See Item 9 on the cover page"
Beneficial ownership means the person or entity that actually enjoys the benefits of owning shares or other assets — such as receiving dividends, voting rights, or price gains — even if the legal title is held in another name. For investors it matters because knowing who truly controls and profits from a company reveals who can influence decisions, exposes potential conflicts of interest or hidden concentration of power, and affects transparency and risk in the stock.
Sole voting power regulatory
"Sole Voting Power 2,301,375.00"
Sole voting power is the exclusive right to cast votes attached to a shareholder’s stock without needing approval from anyone else. Like holding the only remote control for a TV, it lets that holder decide corporate matters such as board members, mergers, and policy changes, making it important to investors because it concentrates control and can strongly influence a company’s strategy and the value of its shares.
Sole dispositive power regulatory
"Sole Dispositive Power 2,301,375.00"
Sole dispositive power is the exclusive legal authority to decide what happens to a security — for example, whether to sell, transfer, or retain shares — without needing anyone else’s permission. Investors care because it signals who truly controls the economic outcome of an investment: like holding the only key to a safe, the holder can realize gains or losses and may trigger regulatory reporting, insider rules, or influence over corporate ownership.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many TARS shares did the Paradigm reporting persons report?

Paradigm BioCapital Advisors LP, Paradigm BioCapital Advisors GP LLC and Senai Asefaw each reported 2,301,375 shares (4.7%); Paradigm BioCapital International Fund Ltd. reported 2,028,487 shares (4.1%). The Adviser, its general partner and Asefaw may be deemed to own shares held by the Fund and managed accounts, so these reports overlap rather than add together.

What TARS share count was used to calculate the reported ownership percentages?

The reported percentages are based on 49,303,413 shares of Tarsus common stock outstanding as of September 25, 2026, as reported by Tarsus in its Form S-3 filed October 13, 2026.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google





87650L103

(CUSIP Number)
09/30/2026

(Date of Event Which Requires Filing of this Statement)


Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)




schemaVersion:


SCHEDULE 13G





SCHEDULE 13G




Comment for Type of Reporting Person: limited liability company


SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G



Paradigm BioCapital Advisors LP
Signature:/s/ David K. Kim
Name/Title:David K. Kim / Authorized Signatory
Date:11/16/2026
Paradigm BioCapital Advisors GP LLC
Signature:/s/ David K. Kim
Name/Title:David K. Kim / Authorized Signatory
Date:11/16/2026
Senai Asefaw, M.D.
Signature:/s/ Senai Asefaw, M.D.
Name/Title:N/A
Date:11/16/2026
Paradigm BioCapital International Fund Ltd.
Signature:/s/ David K. Kim
Name/Title:David K. Kim / Authorized Signatory
Date:11/16/2026

Keep reading